CO6602166A2 - Composiciones de inhibidor virico para uso terapeutico in vivo que comprende una combinacion de (-)- carvona, geraniol y otro componente de aceite escencial - Google Patents

Composiciones de inhibidor virico para uso terapeutico in vivo que comprende una combinacion de (-)- carvona, geraniol y otro componente de aceite escencial

Info

Publication number
CO6602166A2
CO6602166A2 CO12162165A CO12162165A CO6602166A2 CO 6602166 A2 CO6602166 A2 CO 6602166A2 CO 12162165 A CO12162165 A CO 12162165A CO 12162165 A CO12162165 A CO 12162165A CO 6602166 A2 CO6602166 A2 CO 6602166A2
Authority
CO
Colombia
Prior art keywords
carvone
geraniol
combination
essential oil
vivo
Prior art date
Application number
CO12162165A
Other languages
English (en)
Inventor
Christine Coppens
Original Assignee
Cesa Alliance Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6602166(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cesa Alliance Sa filed Critical Cesa Alliance Sa
Publication of CO6602166A2 publication Critical patent/CO6602166A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una composición antivírica que comprende los siguientes componentes: R-(-)-2-metil-5-(prop-1-en-2-il)- ciclohex-2-enona (también llamada (-)-carvona) y S-(+)-2-metil-5-(prop-1-en-2- il)-ciclohex-2-enona (también llamada (÷)-carvona) y (2E)-3,7-dirnetilocta.-2,6- dien-1-ol (también llamado trans-geraniol) en combinación con al menos un componente más elegido entre componentes de aceites esenciales para su uso en el tratamiento y la prevención de enfermedades producidas por virus encapsulados de ADN, virus no encapsulados de ADN, virus encapsulados de ARN y virus no encapsulados de ARN.
CO12162165A 2010-03-26 2012-09-19 Composiciones de inhibidor virico para uso terapeutico in vivo que comprende una combinacion de (-)- carvona, geraniol y otro componente de aceite escencial CO6602166A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10157930A EP2368547B1 (en) 2010-03-26 2010-03-26 Antiviral compositions comprising geraniol and carvone

Publications (1)

Publication Number Publication Date
CO6602166A2 true CO6602166A2 (es) 2013-01-18

Family

ID=42102951

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12162165A CO6602166A2 (es) 2010-03-26 2012-09-19 Composiciones de inhibidor virico para uso terapeutico in vivo que comprende una combinacion de (-)- carvona, geraniol y otro componente de aceite escencial

Country Status (35)

Country Link
US (2) US8980945B2 (es)
EP (2) EP2368547B1 (es)
JP (1) JP5342085B2 (es)
KR (1) KR101340260B1 (es)
CN (1) CN102946876B (es)
AU (1) AU2011231511B2 (es)
BR (1) BR112012024260B1 (es)
CA (1) CA2790087C (es)
CL (1) CL2012002606A1 (es)
CO (1) CO6602166A2 (es)
CY (3) CY1113449T1 (es)
DK (2) DK2368547T3 (es)
EA (1) EA025278B9 (es)
ES (2) ES2392938T3 (es)
HK (1) HK1176019A1 (es)
HR (2) HRP20120964T1 (es)
HU (1) HUE026121T2 (es)
IL (1) IL222048A (es)
LU (1) LU91805B1 (es)
MA (1) MA34074B1 (es)
ME (1) ME02035B (es)
MX (1) MX346412B (es)
MY (2) MY153104A (es)
NZ (1) NZ602602A (es)
PE (2) PE20130065A1 (es)
PL (2) PL2368547T3 (es)
PT (2) PT2368547E (es)
RS (2) RS52544B (es)
SG (1) SG184039A1 (es)
SI (2) SI2368547T1 (es)
SM (2) SMT201200062B (es)
TN (2) TN2012000444A1 (es)
UA (1) UA102497C2 (es)
WO (1) WO2011117424A1 (es)
ZA (2) ZA201208116B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064360A2 (en) 2011-11-03 2013-05-10 Unilever N.V. A personal cleaning composition
CN104023539B (zh) 2011-12-06 2021-08-13 联合利华知识产权控股有限公司 抗微生物组合物
JP2015505835A (ja) 2011-12-06 2015-02-26 ユニリーバー・ナームローゼ・ベンノートシヤープ 抗菌性組成物
BR112014013601B1 (pt) 2011-12-06 2020-04-14 Unilever Nv composições antimicrobianas, método não terapêutico para desinfetar uma superfície e usos não terapêuticos de uma composição
MX347951B (es) 2012-06-27 2017-05-19 Unilever Nv Composicion antimicrobiana.
RU2533254C2 (ru) * 2012-12-29 2014-11-20 Федеральное государственное бюджетное учреждение научно-исследовательский институт детских инфекций Федерального медико-биологического агентства Способ лечения неврологических осложнений при ветряной оспе у детей
TWI463979B (zh) * 2013-04-12 2014-12-11 Nat Defense Medical Ct 檸檬醛用於製備治療局部腎絲球硬化症之藥物的用途
KR20150145314A (ko) 2014-06-18 2015-12-30 원광대학교산학협력단 카르본을 유효성분으로 포함하는 항균 조성물
CN106727628A (zh) * 2016-12-17 2017-05-31 郑州郑先医药科技有限公司 一种治疗慢性腹泻的西药组合物
KR101970281B1 (ko) * 2017-07-28 2019-04-18 고려대학교 산학협력단 리나릴 아세테이트를 포함하는 올메사탄으로 유발된 장운동과다증의 예방 또는 치료용 조성물
CN107648488A (zh) * 2017-09-29 2018-02-02 陈晓阳 一种用于治疗慢性咽炎的丸剂
KR102118181B1 (ko) * 2018-06-12 2020-06-02 광주여자대학교 산학협력단 식물성 정유를 유효성분으로 포함하는 a형 인플루엔자 바이러스에 대한 항바이러스 조성물
RU2707950C1 (ru) * 2018-11-28 2019-12-02 Общество с ограниченной ответственностью "ЭРБИ" Средство для обработки среды пребывания птицы на основе липосом с фитокомпозицией с иммунотропным действием и избирательным антисептическим эффектом и способ его применения
US20200179299A1 (en) * 2018-12-07 2020-06-11 Global Biolife Inc. Composition and method of controlling infectious diseases with functional fragrances
CN110496117B (zh) * 2019-09-30 2022-09-06 中国科学院微生物研究所 一种小分子化合物在抗非洲猪瘟病毒感染中的新应用
CN111012769B (zh) * 2019-12-05 2021-02-12 青海大学 一种用于治疗包虫病的药物组合物、药物制剂及乳剂制备方法
SG10201914042SA (en) * 2019-12-31 2021-07-29 Xj Bio Engineering Int Pte Ltd Feed additive for preventing african swine fever disease or replacing antibiotic growth promoters and methods of making and using the same
WO2021224947A1 (en) * 2020-05-02 2021-11-11 Norouzi Mehdi Formulation of acute respiratory disease control formulation
CN114716327A (zh) * 2020-12-14 2022-07-08 中南民族大学 柏木醇衍生物、其制备方法及其应用
CA3102947A1 (en) * 2020-12-18 2022-06-18 Skymount Medical Us Inc. Nutraceuticals useful in the treatment of coronavirus diseases
CN115141681B (zh) * 2021-03-30 2024-06-21 湖南诺泽生物科技有限公司 挥发油、其制备方法及用途
JP7133820B1 (ja) 2021-06-09 2022-09-09 塩野香料株式会社 コロナウイルス感染症予防用香料組成物及び結合阻害剤
CN113994963B (zh) * 2021-09-26 2023-04-28 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) 一种含有乙酸二氢香芹酯的抑芽剂及其用途
TWI800937B (zh) * 2021-10-01 2023-05-01 奇美醫療財團法人奇美醫院 用於治療登革熱病毒感染之方法
WO2024097158A1 (en) * 2022-11-01 2024-05-10 Ramirez Christina M Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CN117338758B (zh) * 2023-12-06 2024-03-12 北京远大九和药业有限公司 一种药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5667M (es) 1966-03-10 1968-01-02
LU78955A1 (de) * 1978-01-27 1979-09-06 Chimicasa Gmbh Verfahren zur inaktivierung von viren
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
JP6027718B2 (ja) * 2005-11-30 2016-11-16 エーデン リサーチ ピーエルシー チモール、オイゲノール、ゲラニオール、シトラール、及びl−カルボンから選択されたテルペン又はテルペン混合物を含む組成物及び方法
US9403126B2 (en) * 2007-01-10 2016-08-02 The Regents Of The University Of Michigan Ultrafiltration membrane, device, bioartificial organ, and related methods
KR100796312B1 (ko) * 2007-05-23 2008-01-21 주식회사 바이오미스트테크놀로지 게라니얼,네랄 및 유게놀을 유효성분으로 함유하는 동물용소독제 조성물
KR100941595B1 (ko) 2008-06-05 2010-02-11 주식회사 알앤엘바이오 바이러스 억제제로서 유용한 트리테르페노이드계 화합물
KR100950428B1 (ko) 2008-06-05 2010-04-02 주식회사 알앤엘바이오 바이러스 억제제로서 유용한 디아릴헵타노이드계 화합물

Also Published As

Publication number Publication date
RS53435B (en) 2014-12-31
SI2555763T1 (sl) 2014-08-29
AU2011231511B2 (en) 2014-03-20
KR101340260B1 (ko) 2013-12-10
TN2012000444A1 (en) 2014-01-30
EA025278B1 (ru) 2016-12-30
EP2368547A1 (en) 2011-09-28
PT2368547E (pt) 2012-11-20
PE20130065A1 (es) 2013-03-08
AU2011231511A1 (en) 2012-10-18
CN102946876B (zh) 2016-04-06
PL2555763T3 (pl) 2014-09-30
CN102946876A (zh) 2013-02-27
CY1119841T1 (el) 2018-06-27
SI2368547T1 (sl) 2013-01-31
WO2011117424A1 (en) 2011-09-29
PE20141008A1 (es) 2014-09-20
EP2555763B1 (en) 2014-04-30
HRP20120964T1 (en) 2012-12-31
JP2013523622A (ja) 2013-06-17
CL2012002606A1 (es) 2013-10-18
EA201270749A1 (ru) 2013-03-29
US8883859B1 (en) 2014-11-11
BR112012024260A2 (pt) 2016-07-12
TN2013000366A1 (en) 2015-01-20
ME02035B (me) 2013-04-30
DK2555763T3 (da) 2014-08-04
MA34074B1 (fr) 2013-03-05
NZ602602A (en) 2012-12-21
EA025278B9 (ru) 2017-03-31
US20130225676A1 (en) 2013-08-29
CA2790087A1 (en) 2011-09-29
IL222048A (en) 2014-09-30
EP2368547B1 (en) 2012-09-12
BR112012024260B1 (pt) 2019-12-31
ES2392938T3 (es) 2012-12-17
EP2555763A1 (en) 2013-02-13
US8980945B2 (en) 2015-03-17
CY1113449T1 (el) 2016-06-22
HUE026121T2 (en) 2016-05-30
RS52544B (en) 2013-04-30
CY1115375T1 (el) 2017-01-04
ZA201208116B (en) 2014-04-30
PL2368547T3 (pl) 2013-02-28
UA102497C2 (ru) 2013-07-10
DK2368547T3 (da) 2013-01-02
CA2790087C (en) 2013-07-30
HK1176019A1 (en) 2013-07-19
MX346412B (es) 2017-03-17
PT2555763E (pt) 2014-08-04
ES2486765T3 (es) 2014-08-19
JP5342085B2 (ja) 2013-11-13
MY158757A (en) 2016-11-15
HRP20140706T1 (hr) 2014-09-12
LU91805B1 (fr) 2011-09-26
SMT201400104B (it) 2014-09-08
SG184039A1 (en) 2012-10-30
MY153104A (en) 2014-12-31
MX2012010949A (es) 2013-01-29
KR20120128716A (ko) 2012-11-27
SMT201200062B (it) 2013-03-08
ZA201306926B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CO6602166A2 (es) Composiciones de inhibidor virico para uso terapeutico in vivo que comprende una combinacion de (-)- carvona, geraniol y otro componente de aceite escencial
CY1121572T1 (el) Σκευασμα δισκιου του ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου για χρηση στη θεραπεια κυστικης ινωσης
ECSP14013315A (es) Inhibidores de aplicación viral
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
UY31170A1 (es) Compuestos moduladores de sirtuina
BR112015000161A2 (pt) composições de vetor de vírus adeno-associado modificado
CO6470821A2 (es) Pirazinilpirazoles
BR112015001313A2 (pt) composições de vacina
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
EA201290373A1 (ru) Синергическая противовирусная композиция и ее применение
BR112013032049A2 (pt) inibidores do vírus da hepatite c
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
BR112015007879A2 (pt) inibidores do vírus da hepatite c
AR084187A1 (es) Composiciones para el cuidado oral
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
BR112012022209A2 (pt) composições farmacêuticas compreendendo monoterpenos
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
UY30653A1 (es) Antiinflamatorios no esteroideos contra la tos
CO6771455A2 (es) Composición de inhibidor vírico para uso terapéutico in vivo
UY35101A (es) Composiciones plaguicidas y métodos para el control de plagas de invertebrados.
CL2013002761A1 (es) Uso de composicion farmaceutica que comprende catecoles (1,2-dihidroxibencenos) 3,5 disustituidos, util para el tratamiento de enfermedades causadas por virus de adn o arn (no) encapsulados.
TH131426B (th) องค์ประกอบสารยับยั้งไวรัส (Viral inhibitor composition) สำหรับการใช้รักษา โรคภายในสิ่งมีชีวิตที่ประกอบด้วยการรวมของ (-)-คาร์โวน, (+)-คาร์โวน (Carvone), เจรานิออล (Geraniol) และ ส่วนประกอบน้ำมันที่จำเป็นนอกจากนี้

Legal Events

Date Code Title Description
FC Application refused